Senior Director, RWE Virology Product Area Lead - HIV Treatment

United States

Apply with AI Apply

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

The Senior Director, RWE Virology Product Area Lead – HIV Treatment should have direct expertise in the use of Real-World Evidence (RWE) throughout product development and commercialization processes. The role requires the ability to lead and manage cross-functional efforts and resources, and exceptional stakeholder management skills. A strong understanding of epidemiologic study design and execution is essential.

Responsibilities

The Senior Director will be accountable for developing and executing the global RWE strategy for HIV Treatment products, serving as the key RWE subject matter expert for these products across their lifecycle. This includes representing RWE on Global Development Teams and Program Strategy Teams, partnering with clinical development, medical, and commercial teams, and advising on methodological approaches for payer and provider interactions. The role involves leading a team of observational research scientists to generate RWE, including natural history of disease, population characterization, treatment patterns, comparative safety and effectiveness research, and voluntary post-approval studies, ensuring timeliness, quality, and utility.

Skills

Real-World Evidence (RWE)

Real-World Data (RWD)

HIV Treatment

Clinical Data Sciences

Product Strategy

Global Development Teams

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters

1987Year Founded

$15,873.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.

Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.

Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.

Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.

Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.

Investment in digital health technologies enhances Gilead's R&D and patient engagement.

Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI

Try Jobo Free